Loading patent…
AssigneeBoard of Regents, The University of Texas System
InventorsAllen B. Cohen, Edmund J. Miller, Shigeki Nagao, Ferdicia K. Carr
Estimating the term…
The present invention describes a method of preventing neutrophil chemotaxis, either in vitro or at a biological site using peptides whose amino acid sequence is derived at least in part from the sequence of native neutrophil activating factor (NAF). The peptides do not have measurable chemotactic activity against human neutrophils, but they are antagonistic to native NAF. The method of preventing neutrophil chemotaxis is practiced by adding sufficient amounts of the claimed peptides to neutrophils in a biological fluid or appropriate medium to inhibit neutrophil chemotaxis. The claimed peptides may have therapeutic value in patients with Adult Respiratory Distress Syndrome (ARDS) or with other inflammatory lesions known or found to be caused by NAF.
A peptide consisting essentially of 15 to 35 amino acids having a sequence contained in neutrophil activating factor, said peptide being an antagonist of neutrophil activating factor and further being without chemotactic activity.
A peptide consisting essentially of the amino acid sequence:
A peptide consisting essentially of the amino acid sequence:
Dependencies are inferred from the claim text.